BR0007921A - Process for preventing or reducing cardiovascular events associated with coronary intervention - Google Patents

Process for preventing or reducing cardiovascular events associated with coronary intervention

Info

Publication number
BR0007921A
BR0007921A BR0007921-9A BR0007921A BR0007921A BR 0007921 A BR0007921 A BR 0007921A BR 0007921 A BR0007921 A BR 0007921A BR 0007921 A BR0007921 A BR 0007921A
Authority
BR
Brazil
Prior art keywords
coronary intervention
events associated
cardiovascular events
preventing
reducing cardiovascular
Prior art date
Application number
BR0007921-9A
Other languages
Portuguese (pt)
Inventor
Jeffrey R Granett
Neil H Shusterman
David C U Prichard
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0007921A publication Critical patent/BR0007921A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"PROCESSO PARA PREVENçãO OU REDUçãO DE EVENTOS CARDIOVASCULARES ASSOCIADOS COM INTERVENçãO CORONáRIA". Esta invenção provê um processo para a prevenção ou redução de eventos cardiovasculares associados com intervenção coronária em um mamífero, particularmente um humano, que compreende administração ao sujeito ácido N-(3',4'dimetoxi cinamoil) antranílico (N-5') ou um seu sal farmaceuticamente aceitável em uma dose diária a partir de mais que 300mg a cerca de 1200mg por um período de tratamento de até 89 dias em associação com intervenção coronária."PROCESS FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR EVENTS ASSOCIATED WITH CORONARY INTERVENTION". This invention provides a process for the prevention or reduction of cardiovascular events associated with coronary intervention in a mammal, particularly a human, which comprises administration to the subject N- (3 ', 4'dimethoxy cinnamoyl) anthranilic (N-5') or a pharmaceutically acceptable salt thereof in a daily dose from more than 300mg to about 1200mg for a treatment period of up to 89 days in association with coronary intervention.

BR0007921-9A 1999-02-03 2000-02-02 Process for preventing or reducing cardiovascular events associated with coronary intervention BR0007921A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11846299P 1999-02-03 1999-02-03
PCT/US2000/002622 WO2000045811A1 (en) 1999-02-03 2000-02-02 Method for the prevention or reduction of cariovascular events associated with coronary intervention

Publications (1)

Publication Number Publication Date
BR0007921A true BR0007921A (en) 2002-09-10

Family

ID=22378750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007921-9A BR0007921A (en) 1999-02-03 2000-02-02 Process for preventing or reducing cardiovascular events associated with coronary intervention

Country Status (17)

Country Link
EP (1) EP1171116A4 (en)
JP (1) JP2002536327A (en)
KR (1) KR20010101934A (en)
CN (1) CN1345237A (en)
AU (1) AU2636600A (en)
BR (1) BR0007921A (en)
CA (1) CA2361581A1 (en)
CO (1) CO5150206A1 (en)
HK (1) HK1045104A1 (en)
HU (1) HUP0200129A3 (en)
IL (1) IL144721A0 (en)
MX (1) MXPA01007835A (en)
NO (1) NO20013788L (en)
PL (1) PL351397A1 (en)
TR (1) TR200102245T2 (en)
WO (1) WO2000045811A1 (en)
ZA (1) ZA200106353B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617407B2 (en) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 Preventive and therapeutic agent for intimal cell hyperproliferative disease
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
KR19990044478A (en) * 1995-09-07 1999-06-25 간자와 무츠와 2-acylaminobenzamide derivatives and preventive and therapeutic agents for diseases caused by vascular endothelial hyperplasia
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention

Also Published As

Publication number Publication date
KR20010101934A (en) 2001-11-15
EP1171116A1 (en) 2002-01-16
TR200102245T2 (en) 2002-05-21
PL351397A1 (en) 2003-04-07
CN1345237A (en) 2002-04-17
MXPA01007835A (en) 2002-04-24
NO20013788D0 (en) 2001-08-02
WO2000045811A1 (en) 2000-08-10
JP2002536327A (en) 2002-10-29
HUP0200129A2 (en) 2002-05-29
NO20013788L (en) 2001-09-28
HK1045104A1 (en) 2002-11-15
CA2361581A1 (en) 2000-08-10
AU2636600A (en) 2000-08-25
ZA200106353B (en) 2002-08-02
CO5150206A1 (en) 2002-04-29
EP1171116A4 (en) 2004-11-17
IL144721A0 (en) 2002-06-30
HUP0200129A3 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
BR0013122A (en) Cyclobenzaprine for treatment of generalized anxiety disorder and cyclobenzaprine compositions
BR0115109A (en) Therapeutic agents and methods of their use for angiogenesis modulation
BR0008059A (en) Compositions of valdecoxib
BR0013540A (en) Pharmaceutical formulations and their use in preventing stroke, diabetes and / or congestive heart failure.
BR0115166A (en) Drug combinations (eg chlorpromazine and pentamidine) for the treatment of neoplastic disorders
BR9911072A (en) Preparations for the application of anti-inflammatory agents, especially antiseptics and / or agents that promote wound healing in the lower respiratory tract
ATE282418T1 (en) ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID
EA200501496A1 (en) HIGH-SELECTIVE INHIBITORS OF REVERSE CAPTURE OF NOREPINEFRIN AND METHODS OF THEIR APPLICATION
BRPI0411255A (en) compound, pharmaceutical composition, use of a compound, methods of treating a disorder of a patient, and process for the preparation of a compound
KR970704429A (en) USE OF DROLOXIFENE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
BR0111591A (en) Compounds, pharmaceutical composition, and methods for elevating the growth hormone plasma level in a mammal, for the treatment of growth hormone secretion deficiency, for the treatment of growth retardation in children, for the treatment of metabolic disorders growth hormone secretion deficiency, particularly in elderly patients, and to promote wound healing, surgical recovery or recovery from debilitating diseases
BR9709838A (en) Administration regimen that provides a blood plasma profile of an h +, k + -atpase inhibitor oral pharmaceutical composition and the use of h +, k + -atpase inhibitor and processes to improve the inhibition of gastric acid secretion and the therapeutic effect on treatment of gastrointestinal disorders and to receive an extended plasma profile of an h +, k + -atpase inhibitor
AU1794601A (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
BR0015407A (en) Compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods to stimulate the release of growth hormone from a mammal's pituitary gland and to increase the rate and degree of growth, the production of milk and wool or for the treatment of and use of a compound or a pharmaceutically acceptable salt of the same
BR9713921A (en) Compound, pharmaceutical composition, process for logician capable of being modulated through factor xa inhibition
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
KR970061244A (en) Pharmaceutical composition for treating dementia
BR0214075A (en) Unit dosage comprising a prostaglandin analog to treat constipation
BR9809678A (en) Triptolyte derivatives useful in the treatment of autoimmune diseases
BRPI0410654A (en) compound, pharmaceutical composition, use of a compound, method for treating a disorder of a patient, and process for the preparation of a compound
KR950031063A (en) Using pravastatin to slow the progression of coronary atherosclerosis
ATE448788T1 (en) TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH 2-METHYLENE-19-NOR-VITAMIN D COMPOUNDS
BR0211855A (en) Drug and method for treating and improving restorative sleep quality
BR0307022A (en) Method of treating a patient who needs analgesia
BR0007921A (en) Process for preventing or reducing cardiovascular events associated with coronary intervention

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]